Orient Pharma Statistics

Total Valuation

Orient Pharma has a market cap or net worth of TWD 8.14 billion. The enterprise value is 8.42 billion.

Market Cap	8.14B
Enterprise Value	8.42B

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Orient Pharma has 223.04 million shares outstanding. The number of shares has decreased by -0.42% in one year.

Current Share Class	223.04M
Shares Outstanding	223.04M
Shares Change (YoY)	-0.42%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.08%
Owned by Institutions (%)	n/a
Float	33.55M

Valuation Ratios

The trailing PE ratio is 67.59.

PE Ratio	67.59
Forward PE	n/a
PS Ratio	6.44
PB Ratio	4.43
P/TBV Ratio	5.89
P/FCF Ratio	28.72
P/OCF Ratio	26.32
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 28.86, with an EV/FCF ratio of 29.70.

EV / Earnings	70.18
EV / Sales	6.66
EV / EBITDA	28.86
EV / EBIT	53.37
EV / FCF	29.70

Financial Position

The company has a current ratio of 1.69, with a Debt / Equity ratio of 0.26.

Current Ratio	1.69
Quick Ratio	0.97
Debt / Equity	0.26
Debt / EBITDA	1.67
Debt / FCF	1.72
Interest Coverage	12.08

Financial Efficiency

Return on equity (ROE) is 6.64% and return on invested capital (ROIC) is 4.81%.

Return on Equity (ROE)	6.64%
Return on Assets (ROA)	3.84%
Return on Invested Capital (ROIC)	4.81%
Return on Capital Employed (ROCE)	7.61%
Revenue Per Employee	7.31M
Profits Per Employee	693,277
Employee Count	173
Asset Turnover	0.49
Inventory Turnover	2.19

Taxes

In the past 12 months, Orient Pharma has paid 58.63 million in taxes.

Income Tax	58.63M
Effective Tax Rate	32.83%

Stock Price Statistics

The stock price has increased by +30.59% in the last 52 weeks. The beta is -0.08, so Orient Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.08
52-Week Price Change	+30.59%
50-Day Moving Average	34.54
200-Day Moving Average	34.26
Relative Strength Index (RSI)	54.39
Average Volume (20 Days)	32,822

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Orient Pharma had revenue of TWD 1.26 billion and earned 119.94 million in profits. Earnings per share was 0.54.

Revenue	1.26B
Gross Profit	656.44M
Operating Income	157.73M
Pretax Income	178.57M
Net Income	119.94M
EBITDA	272.07M
EBIT	157.73M
Earnings Per Share (EPS)	0.54

Full Income Statement

Balance Sheet

The company has 210.55 million in cash and 487.27 million in debt, giving a net cash position of -276.72 million or -1.24 per share.

Cash & Cash Equivalents	210.55M
Total Debt	487.27M
Net Cash	-276.72M
Net Cash Per Share	-1.24
Equity (Book Value)	1.84B
Book Value Per Share	8.37
Working Capital	322.04M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 309.28 million and capital expenditures -25.83 million, giving a free cash flow of 283.45 million.

Operating Cash Flow	309.28M
Capital Expenditures	-25.83M
Free Cash Flow	283.45M
FCF Per Share	1.27

Full Cash Flow Statement

Margins

Gross margin is 51.94%, with operating and profit margins of 12.48% and 9.49%.

Gross Margin	51.94%
Operating Margin	12.48%
Pretax Margin	14.13%
Profit Margin	9.49%
EBITDA Margin	21.53%
EBIT Margin	12.48%
FCF Margin	22.43%

Dividends & Yields

Orient Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.42%
Shareholder Yield	n/a
Earnings Yield	1.47%
FCF Yield	3.48%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on May 23, 2016. It was a reverse split with a ratio of 0.6500936135.

Last Split Date	May 23, 2016
Split Type	Reverse
Split Ratio	0.6500936135

Scores

Altman Z-Score	n/a
Piotroski F-Score	7